TABLE 2

Risk Factors for Disease Progression During Follow-up at Univariate and Multivariate Analysis

	Univariate			Multivariate
Patient characteristic	HR	95% confidence interval	P	HR	95% confidence interval	P
Sex (male vs. female)^*	0.80	0.40–1.61	0.532	—	—	—
Syndrome (no vs. yes)^*	1.86	0.71–4.89	0.205	—	—	—
Stage IV vs. IIIB^*	1.87	0.71–4.94	0.209	3.31	1.16–9.47	0.026
NET G2 vs. NET G1	1.94	0.86–4.35	0.109
Ki-67 (>5% vs. ≤5%)^*	2.89	1.31–6.34	0.009	3.24	1.34–7.84	0.009
Ki-67 (continuous)	1.09	1.02–1.17	0.009
SUV_max (≤37.8 vs. ≥38.0)^*	3.09	1.46–6.57	0.003	2.37	1.03–5.47	0.043
Therapy (medical vs. PRRT)^*	2.36	1.16–4.80	0.018	2.70	1.21–6.03	0.015

↵* Variables in multivariate analysis.